OmniCAR is the world’s first universal immune receptor system that leverages the high-fidelity nature of covalent chemistry. Originating from Oxford University and University of Pennsylvania, OmniCAR has the capability of addressing multiple technical hurdles faced by conventional CAR-T therapies including exhaustion, antigen heterogeneity/escape and control of CAR activity in vivo. Prescient has licensed and is developing OmniCAR to treat some of the most intractable cancers, including relapsed/refractory acute myeloid leukaemia. We will present early evidence showing that OmniCAR can be armed both sequentially and simultaneously, with real-time tumour killing studies. We will showcase some of the core attributes of OmniCAR such as its predictable and controllable CAR activity using minimal amounts of targeting ligand. Our strategy for clinical development will also be discussed.